GnRH Agonist Treatment For Prostrate Cancer Increases Diabetes Risk in Men促性腺激素释放激素激动剂治疗前列腺癌的增加,糖尿病的风险在男子
Sunday, April 30th, 2006 周日, 2006年4月30日According to Boston-based researchers, Gonadotropin-releasing hormone (GnRH) agonist treatment for prostate cancer might increase the chances of diabetes development in nondiabetic men.据总部设在波士顿的研究人员,促性腺激素释放激素( GnRH )激动剂治疗前列腺癌可能会增加糖尿病的机会,发展在nondiabetic男子。 This observation suggests that hormone therapy increases risk for (type 2) diabetes, a condition defined by insulin resistance.这个观察表明,激素治疗增加的风险( 2型)糖尿病,条件所界定的胰岛素抵抗。
































